FDA guidance on cell/tissue donor screening test:
This article was originally published in Clinica
The FDA has issued a guidance on how manufacturers, which currently sell test kits to screen for the presence of disease in a cadaveric blood specimen, can expand the indication so the test can be used to screen for disease in donors of human cells, tissues and cellular and tissue-based products. Such a screening test is now necessary in the wake of a recent final rule requiring that donors of cells and tissue be tested for the presence of certain communicable diseases. Currently, only one company - Genetic Systems, a subsidiary of Sanofi Diagnostics Pasteur - markets a test kit for cadaveric blood specimens.
You may also be interested in...
As sector awaits its aducanumab filing with bated breath, Biogen invests again in early stage neuroscience.
In case you missed it: catch up with snippets from interviews with industry leaders recently published by In Vivo.
While good clinical practice inspectors in the UK and the US collaborate on matters of common interest, they say that mutual recognition is simply not possible.